Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Modern Rheumatology
Published in: Modern Rheumatology 4/2012

01-08-2012 | Case Report

Development of germinoma during the treatment of systemic-onset juvenile idiopathic arthritis with infliximab

Authors: Shunichiro Takezaki, Yuka Okura, Mizuho Ichikawa, Daisuke Suzuki, Junjiro Ohshima, Makoto Kaneda, Yuko Cho, Masafumi Yamada, Nobuaki Kawamura, Akihiro Iguchi, Ichiro Kobayashi, Tadashi Ariga

Published in: Modern Rheumatology | Issue 4/2012

Login to get access

Abstract

We report a 19-year-old patient with systemic-onset juvenile idiopathic arthritis (JIA) who developed a mediastinal germinoma during treatment with infliximab. Although the cancer risk of infliximab is controversial, this agent may have accelerated the growth of the germinoma. We conclude that the indications for tumor necrosis factor (TNF) inhibitors should be strictly decided and that a nationwide cohort study is necessary to assess the risk of cancer in patients with JIA exposed to biologics.
Literature
1.
2.
Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–101.PubMedCrossRef
3.
Pain CE, McCann LJ. Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics. 2009;3:127–39.PubMed
4.
Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy of repeated intravenous infusion of an anti-tumor necrosis factor-a monoclonal antibody, infliximab, in persistently active refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum. 2005;52:548–53.PubMedCrossRef
5.
Lamot L, Bukovac LT, Vidovic M, Frleta M, Harjacek M. The ‘head-to-head’ comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011;29:131–9.PubMed
6.
Lahdenne P, Vähäsalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003;62:245–7.PubMedCrossRef
7.
Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62:2517–24.PubMedCrossRef
8.
Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.PubMedCrossRef
9.
Geborek P, Bladström A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699–703.PubMedCrossRef
10.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.PubMedCrossRef
11.
Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1421–6.PubMedCrossRef
12.
Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136–45.PubMedCrossRef
13.
Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56:1433–9.PubMedCrossRef
14.
Horneff G, Foeldvari I, Minden K, Moebius D, Hospach T. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford). 2011;50:230–6.CrossRef
15.
Baecklund E, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998;317:180–1.PubMedCrossRef
16.
Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum. 2010;62:3776–82.PubMedCrossRef
17.
McCroskery P, Wallace CA, Lovell DJ, Stryker S, Chernyukhin N, Blosch C, Zack DJ. Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol 2010;8:18. doi:10.​1186/​1546-0096-8-18.
18.
Trulson A, Nilsson S, Venge P. Monocyte activation in patients with nonseminomatous germ cell tumour of the testis before and after tumour eradication. J Clin Pathol. 1996;49:381–5.PubMedCrossRef
19.
Purdue MP, Sakoda LC, Graubard BI, et al. Polymorphisms and risk of testicular germ cell tumors: a case-control investigation of immune function gene. Cancer Epidemiol Biomarkers Prev. 2007;16:77–83.PubMedCrossRef
Metadata
Title
Development of germinoma during the treatment of systemic-onset juvenile idiopathic arthritis with infliximab
Authors
Shunichiro Takezaki
Yuka Okura
Mizuho Ichikawa
Daisuke Suzuki
Junjiro Ohshima
Makoto Kaneda
Yuko Cho
Masafumi Yamada
Nobuaki Kawamura
Akihiro Iguchi
Ichiro Kobayashi
Tadashi Ariga
Publication date
01-08-2012
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 4/2012
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-011-0555-z

Other articles of this Issue 4/2012

Modern Rheumatology 4/2012 Go to the issue

Rapid Communication

Radiographic remodeling of the shoulder joint in a patient with rheumatoid arthritis after 4 years of treatment with etanercept

Original Article

Effects of APRIL (TNFSF13) polymorphisms and splicing isoforms on the secretion of soluble APRIL

Original Article

Tocilizumab-induced hyperbilirubinemia in Japanese patients with rheumatoid arthritis: its association with UDP glucuronosyltransferase 1A1 gene polymorphisms

Original Article

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients

Case Report

Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies

Original Article

Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits